VIA
ARKG icon

Vantage Investment Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Vantage Investment Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$8K Hold
230
– – ﹤0.01% 563
2018
Q2 		$7K Buy
230
+30
+15% +$835 ﹤0.01% 589
2018
Q1 		$5K Buy
+200
New +$5.42K ﹤0.01% 657

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SI
Stephens Inc Little Rock, Arkansas $7.99B AUM 21.6% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
EFS
Edelman Financial Services Fairfax, Virginia $11B AUM 9.53% 1-Year Est. Return
MIAN
Mariner Independent Advisor Network Overland Park, Kansas $2.33B AUM 14.85% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return

Vantage Investment Advisors's ARKG Position: Q3 2018 in Review

Vantage Investment Advisors held its ARK Genomic Revolution ETF (ARKG) position steady in Q3 2018 at 230 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #563.

Vantage Investment Advisors first reported a position in ARKG in Q1 2018 and has held it in 3 quarters since. 58 funds tracked by Wall St. Rank hold ARKG as of Q3 2018.

  • Vantage Investment Advisors held 230 shares of ARK Genomic Revolution ETF worth $8K as of Q3 2018.
  • Vantage Investment Advisors left its ARK Genomic Revolution ETF share count unchanged in Q3 2018.
  • ARK Genomic Revolution ETF made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #563 holding.
  • Vantage Investment Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2018 and has held it in 3 quarters since.
  • 58 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.